Clinical Trial Update: Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a multi-targeted recombinant vaccine (Ad5 PSA/MUC1/Brachyury) for castration-resistant prostate cancer; completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• Ad5 PSA/MUC1/Brachyury-based immunotherapy vaccine (not specified)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasms, Prostatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-12-22